Blake D. Babcock

High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal

Blake D. Babcock, Mayada Aljehani, Brice Jabo et al. · Annals of Surgical Oncology · 2018 · 118 citations

Epidemiology, Surgical Oncology, Cancer Risk +11

Emerging Role of MDM2 as Target for Anti-Cancer Therapy: A Review.

Mohammad F. Shaikh, William F. Morano, J. Jack Lee et al. · PubMed · 2016 · 61 citations

Mdm2 Amplification, Chemoprevention Strategy, Apoptosis +19

Gastric Cancer Peritoneal Carcinomatosis Risk Score

Liang Ji, Matthew J. Selleck, Jane Xu et al. · Annals of Surgical Oncology · 2019 · 31 citations · Full text

The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.

Katlin Davitt, Blake D. Babcock, Maly Fenelus et al. · PubMed · 2014 · 18 citations

Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino enhancer of split protein of the Notch complex

Blake D. Babcock, B W Anderson, Ioannis A. Papayannopoulos et al. · Molecular Immunology · 1998 · 16 citations

Immunogenetics, Signal Transduction, Breast Cytotoxic T +9